肠道黏膜免疫在IgA肾病发病机制中的研究进展
Research Progress on Intestinal Mucosal Immunity in the Pathogenesis of IgA Nephropathy
DOI: 10.12677/acm.2026.1672759, PDF,   
作者: 全奕晓*, 白彝华#：昆明医科大学第二附属医院肾脏内科，云南 昆明
关键词: IgA肾病；粘膜免疫；肠道菌群；食物抗原；肠道疾病；IgA Nephropathy； Mucosal Immunity； Gut Microbiota； Food Antigen； Intestinal Diseases
摘要: IgA肾病是全球最常见的原发性肾小球疾病，其发病机制与半乳糖缺陷型IgA1的产生及其自身抗体的形成密切相关。越来越多的证据表明，肠道作为产生IgA的主要场所，其黏膜免疫系统的异常是IgA肾病的关键始动因素。本综述系统阐述了肠道菌群失调、膳食抗原暴露及肠道疾病等多种因素如何导致肠道黏膜免疫异常，进而驱动IgA肾病的发病。同时，我们针对上述机制，相对应地探讨了其潜在的治疗策略，以期为理解IgA肾病的“肠–肾轴”机制和开发新型疗法提供视角。
Abstract: IgA nephropathy is the most common primary glomerular disease globally, and its pathogenesis is closely related to the production of galactose-deficient IgA1 and the formation of autoantibodies. Increasing evidence suggests that abnormalities in the intestinal mucosal immune system, as the primary site of IgA production, are a key initiating factor in IgA nephropathy. This review systematically elaborates on how various factors, such as intestinal flora imbalance, dietary antigen exposure, and intestinal diseases, can lead to abnormalities in intestinal mucosal immunity, thereby driving the pathogenesis of IgA nephropathy. Simultaneously, we explore potential therapeutic strategies corresponding to the aforementioned mechanisms, aiming to provide insights into understanding the “gut-kidney axis” mechanism of IgA nephropathy and developing novel therapies.
文章引用：全奕晓, 白彝华. 肠道黏膜免疫在IgA肾病发病机制中的研究进展[J]. 临床医学进展, 2026, 16(7): 2300-2309. https://doi.org/10.12677/acm.2026.1672759

参考文献

[1] Wang, Y.N., Gan, T., Qu, S., Xu, L., Hu, Y., Liu, L., et al. (2023) MTMR3 Risk Alleles Enhance Toll Like Receptor 9-Induced IgA Immunity in IgA Nephropathy. Kidney International, 104, 562-576.
https://doi.org/10.1016/j.kint.2023.06.018
[2] Trimarchi, H. (2025) Moving from the Four-to the Five-Hit Hypothesis in IgA Nephropathy. 18th International Symposium on IgA Nephropathy (IIgANN 2025), Prague, 17-20 September 2025.
[3] Isho, B., Florescu, A., Wang, A.A. and Gommerman, J.L. (2021) Fantastic IgA Plasma Cells and Where to Find Them. Immunological Reviews, 303, 119-137.
https://doi.org/10.1111/imr.12980
[4] 唐余燕, 孙蔚倩, 贺海东, 等. 肠黏膜TLR4/NF-κB通路激活与伪无菌IgA肾病小鼠肾损害有关[J]. 细胞与分子免疫学杂志, 2023, 39(10): 865-871.
[5] Tangon, N., Kumfu, S., Chattipakorn, N. and Chattipakorn, S.C. (2025) Links between Oropharyngeal Microbiota and Iga Nephropathy: A Paradigm Shift from Isolated Microbe to Microbiome. Microbiological Research, 292, Article 128005.
https://doi.org/10.1016/j.micres.2024.128005
[6] Dong, Y., Yan, G., Zhang, Y., Zhou, Y. and Shang, J. (2025) Gut Microbiota as a Predictive Tool for Outcomes in IgA Nephropathy. Renal Failure, 47, Article 2514184.
https://doi.org/10.1080/0886022x.2025.2514184
[7] Zhu, Y., He, H., Sun, W., Wu, J., Xiao, Y., Peng, Y., et al. (2024) IgA Nephropathy: Gut Microbiome Regulates the Production of Hypoglycosilated IgA1 via the TLR4 Signaling Pathway. Nephrology Dialysis Transplantation, 39, 1624-1641.
https://doi.org/10.1093/ndt/gfae052
[8] 包文晗, 唐雯. 初诊IgA肾病患者的肠道菌群及其与疾病进展因素的相关分析[J]. 北京大学学报(医学版), 2023, 55(1): 124-132.
[9] Sallustio, F., Curci, C., Chaoul, N., Fontò, G., Lauriero, G., Picerno, A., et al. (2021) High Levels of Gut-Homing Immunoglobulin A+ B Lymphocytes Support the Pathogenic Role of Intestinal Mucosal Hyperresponsiveness in Immunoglobulin a Nephropathy Patients. Nephrology Dialysis Transplantation, 36, 452-464.
https://doi.org/10.1093/ndt/gfaa264
[10] Popova, A., Rācenis, K., Brīvība, M., Saksis, R., Saulīte, M., Šlisere, B., et al. (2025) Reduced Butyrate-Producing Bacteria and Altered Metabolic Pathways in the Gut Microbiome of Immunoglobulin a Nephropathy Patients. Scientific Reports, 15, Article No. 28011.
https://doi.org/10.1038/s41598-025-13629-5
[11] Gleeson, P.J., Benech, N., Chemouny, J., Metallinou, E., Berthelot, L., da Silva, J., et al. (2024) The Gut Microbiota Posttranslationally Modifies IgA1 in Autoimmune Glomerulonephritis. Science Translational Medicine, 16, Article No. 15.
https://doi.org/10.1126/scitranslmed.adl6149
[12] Carney, E.F. (2024) Role of the Gut Microbiota in the Pathogenesis of Iga Nephropathy. Nature Reviews Nephrology, 20, 353-353.
https://doi.org/10.1038/s41581-024-00845-x
[13] Huang, Y., Zhou, J., Wang, S., Xiong, J., Chen, Y., Liu, Y., et al. (2020) Indoxyl Sulfate Induces Intestinal Barrier Injury through IRF1-DRP1 Axis-Mediated Mitophagy Impairment. Theranostics, 10, 7384-7400.
https://doi.org/10.7150/thno.45455
[14] Tang, Y.Y., Zhang, D.L., Huang, L.S., Hu, P., Liu, P., Wu, J., et al. (2025) Gut Microbial Metabolite, Sphingosine-1-Phosphate (S1P), Drives Mesangial Cell Phenotypic Transformation and Accelerates Progression of IgA Nephropathy via CCL2-MET-FAK Pathway. Current Research in Microbial Sciences, 9, Article 100494.
https://doi.org/10.1016/j.crmicr.2025.100494
[15] Gleeson, P.J. and Monteiro, R.C. (2024) The Role of Mucosal Immunity: What Can We Learn from Animal and Human Studies? Seminars in Nephrology, 44, Article 151566.
https://doi.org/10.1016/j.semnephrol.2025.151566
[16] Yamasaki, M., Miyamoto, Y., Ogawa, K., Nishiyama, K., Tsend-Ayush, C., LI, Y., et al. (2024) Lactiplantibacillus plantarum 06CC2 Upregulates Intestinal ZO-1 Protein and Bile Acid Metabolism in Balb/C Mice Fed High-Fat Diet. Bioscience of Microbiota, Food and Health, 43, 13-22.
https://doi.org/10.12938/bmfh.2023-002
[17] Li, C., Wen, Q., Zhang, Y. and Wu, J. (2025) Causal Associations between Environmental Factors and Risk of Iga Nephropathy and Membranous Nephropathy: A Bidirectional Mendelian Randomization and Mediation Analysis. Renal Failure, 47, Article 2486620.
https://doi.org/10.1080/0886022x.2025.2486620
[18] Geng, Y., Zhang, Z., Zhang, J., Huang, B., Guo, Z., Wang, X., et al. (2022) Hyperuricemia Aggravates the Progression of Iga Nephropathy. International Urology and Nephrology, 54, 2227-2237.
https://doi.org/10.1007/s11255-022-03125-4
[19] Hu, M., Zhou, Y., Zhang, Y., Pan, F. and Liu, M. (2026) Febuxostat Alleviates Gout-Associated Hyperuricemia and Inflammation by Downregulating IL1A to Modulate TLR2/TLR4/NF-κB Signaling Pathway. International Immunopharmacology, 168, Article 115935.
https://doi.org/10.1016/j.intimp.2025.115935
[20] Silva, C.R., Saraiva, A.L., Rossato, M.F., Trevisan, G. and Oliveira, S.M. (2023) What Do We Know about Toll-Like Receptors Involvement in Gout Arthritis? Endocrine, Metabolic & Immune Disorders-Drug Targets, 23, 446-457.
https://doi.org/10.2174/1871530322666220523145728
[21] Fasano, A. (2020) All Disease Begins in the (leaky) Gut: Role of Zonulin-Mediated Gut Permeability in the Pathogenesis of Some Chronic Inflammatory Diseases. F1000Research, 9, Article 69.
https://doi.org/10.12688/f1000research.20510.1
[22] Lian, X., Wang, Y., Wang, S., Peng, X., Wang, Y., Huang, Y., et al. (2023) Does Inflammatory Bowel Disease Promote Kidney Diseases: A Mendelian Randomization Study with Populations of European Ancestry. BMC Medical Genomics, 16, Article No. 225.
https://doi.org/10.1186/s12920-023-01644-2
[23] Xiao, M., Ran, Y., Shao, J., Lei, Z., Chen, Y. and Li, Y. (2022) Causal Association between Inflammatory Bowel Disease and Iga Nephropathy: A Bidirectional Two-Sample Mendelian Randomization Study. Frontiers in Genetics, 13, Article ID: 1002928.
https://doi.org/10.3389/fgene.2022.1002928
[24] Akiyama, M., Shimomura, K., Yoshimoto, H., Sako, M., Kodama, M., Abe, K., et al. (2022) Crohn’s Disease May Promote Inflammation in IgA Nephropathy: A Case-Control Study of Patients Undergoing Kidney Biopsy. Virchows Archiv, 481, 553-563.
https://doi.org/10.1007/s00428-022-03373-w
[25] Liu, X.Z., Zhang, Y.M., Jia, N.Y. and Zhang, H. (2020) Helicobacter pylori Infection Is Associated with Elevated Galactose-Deficient IgA1 in IgA Nephropathy. Renal Failure, 42, 539-546.
https://doi.org/10.1080/0886022x.2020.1772295
[26] Pohjonen, J.T., Kaukinen, K.M., Metso, M.J., Nurmi, R.K., Huhtala, H.S., Pörsti, I.H., et al. (2022) Presence of Gastrointestinal Symptoms in IgA Nephropathy: A Cross-Sectional Study. BMC Nephrology, 23, Article No. 395.
https://doi.org/10.1186/s12882-022-03019-8
[27] Tan, J.X., Dong, L.Q., Jiang, Z., Tan, L., Luo, X., Pei, G., et al. (2022) Probiotics Ameliorate IgA Nephropathy by Improving Gut Dysbiosis and Blunting NLRP3 Signaling. Journal of Translational Medicine, 20, Article No. 382.
https://doi.org/10.1186/s12967-022-03585-3
[28] Zhang, R., Tang, Y., Feng, X., Lu, X., Zhao, M., Jin, J., et al. (2025) Targeted Modulation of Intestinal Barrier and Mucosal Immune-Related Microbiota Attenuates IgA Nephropathy Progression. Gut Microbes, 17, Article 2458184.
https://doi.org/10.1080/19490976.2025.2458184
[29] 李流芳, 黄玉平, 张慧敏, 等. 布地奈德肠溶胶囊联合益生菌制剂在IgA肾病患者治疗中的效果[J]. 中外医学研究, 2026, 24(3): 66-68.
[30] Efficacy and Safety of Probiotics Combined with Enteric-Coated Budesonide Capsules in Patients with Primary IgA Nephropathy.
https://clinicaltrials.gov/study/NCT06528015
[31] Lauriero, G., Abbad, L., Vacca, M., Celano, G., Chemouny, J.M., Calasso, M., et al. (2021) Fecal Microbiota Transplantation Modulates Renal Phenotype in the Humanized Mouse Model of IgA Nephropathy. Frontiers in Immunology, 12, Article ID: 694787.
https://doi.org/10.3389/fimmu.2021.694787
[32] 古再丽努尔·赛来阿吉木, 哈依努尔, 穆福娜依·艾尔肯, 等. 粪菌移植对IgA肾病大鼠模型的治疗作用[J]. 中华肾脏病杂志, 2025, 41(7): 531-539.
[33] Zhi, W., Li, A., Wang, Q., Yuan, X., Qing, J., Zhang, C., et al. (2024) Safety and Efficacy Assessment of Fecal Microbiota Transplantation as an Adjunctive Treatment for Iga Nephropathy: An Exploratory Clinical Trial. Scientific Reports, 14, Article No. 22935.
https://doi.org/10.1038/s41598-024-74171-4
[34] Sun, S.R. (2023) Safety and Efficacy of Fecal Microbiota Transplantation in the Treatment of IgA Nephropathy: A Randomized Controlled Clinical Trial. Chinese Clinical Trial Registry.
https://www.chictr.org.cn/showproj.html?proj=199097
[35] Di Leo, V., Gleeson, P.J., Sallustio, F., Bounaix, C., Da Silva, J., Loreto, G., et al. (2021) Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model. Journal of Personalized Medicine, 11, Article 309.
https://doi.org/10.3390/jpm11040309
[36] Ting, S.Y., Martínez-García, E., Huang, S., Bertolli, S.K., Kelly, K.A., Cutler, K.J., et al. (2020) Targeted Depletion of Bacteria from Mixed Populations by Programmable Adhesion with Antagonistic Competitor Cells. Cell Host & Microbe, 28, 313-321.E6.
https://doi.org/10.1016/j.chom.2020.05.006
[37] Mantsaeva, M.E., Borisov, A.G., Smirnova, M.A. and Stremoukhov, A.A. (2023) The Effectiveness of a Gluten-Free Diet in Patients with IgA Nephropathy. Lechaschi Vrach, 26, 43-47.
https://doi.org/10.51793/os.2023.26.3.007
[38] Yu, D., Zhu, L., Gao, M., Yin, Z., Zhang, Z., Zhu, L., et al. (2023) A Comparative Study of the Effects of Whole Cereals and Refined Cereals on Intestinal Microbiota. Foods, 12, Article 2847.
https://doi.org/10.3390/foods12152847
[39] Luna-Castillo, K.P., Olivares-Ochoa, X.C., Hernández-Ruiz, R.G., Llamas-Covarrubias, I.M., Rodríguez-Reyes, S.C., Betancourt-Núñez, A., et al. (2022) The Effect of Dietary Interventions on Hypertriglyceridemia: From Public Health to Molecular Nutrition Evidence. Nutrients, 14, Article 1104.
https://doi.org/10.3390/nu14051104
[40] Zeb, F., Osaili, T., Obaid, R., Naja, F., Radwan, H., Cheikh Ismail, L., et al. (2023) Gut Microbiota and Time-Restricted Feeding/Eating: A Targeted Biomarker and Approach in Precision Nutrition. Nutrients, 15, Article 259.
https://doi.org/10.3390/nu15020259
[41] Zhang, K., Tang, L., Jiang, S., Wang, Y., Meng, Y., Wang, M., et al. (2022) Is Hyperuricemia an Independent Prognostic Factor for IgA Nephropathy: A Systematic Review and Meta-Analysis of Observational Cohort Studies. Renal Failure, 44, 70-80.
https://doi.org/10.1080/0886022x.2021.2019589
[42] Yandian, F., Caravaca-Fontán, F., Herrera Hernandez, L.P., Soler, M.J., Sethi, S. and Fervenza, F.C. (2024) Kidney Diseases Associated with Inflammatory Bowel Disease: Impact of Chronic Histologic Damage, Treatments, and Outcomes. Kidney International Reports, 9, 383-394.
https://doi.org/10.1016/j.ekir.2023.11.011
[43] Yang, Z., Xu, X., Dong, Y., Wu, K., Zhao, S. and Zhang, Y. (2024) Crohn’s Disease-Associated Iga Nephropathy May Prone to Better Renal Outcome. International Urology and Nephrology, 56, 3815-3824.
https://doi.org/10.1007/s11255-024-04106-5
[44] 王玉路, 薛现军, 刘敏洁, 侯盈苹, 苗月亭. 抗幽门螺杆菌感染在原发性IgAN治疗中的价值[J]. 深圳中西医结合杂志, 2023, 33(11): 17-20.
[45] Barratt, J., Stone, A. and Kristensen, J. (2021) Pos-830 Nefecon for the Treatment of IgA Nephropathy in Patients at Risk of Progressing to End-Stage Renal Disease: The Nefigard Phase 3 Trial Results. Kidney International Reports, 6, S361.
https://doi.org/10.1016/j.ekir.2021.03.868
[46] Calliditas Therapeutics AB (2024) Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients with Primary IgA Nephropathy.
https://clinicaltrials.gov/study/NCT06712407
[47] Borges, R.D.S., Santos, R.L., de Paula, L.H., et al. (2026) Efficacy, Safety, and Biomarker Changes of B-Cell Activating Factor-and A Proliferation-Inducing Ligand-Targeted Therapies in IgA Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Nephrology, 39, 50-62.
[48] Song, H., Liang, G.Q., Yu, M.S., Shan, Y., Shi, J., Jiang, C., et al. (2024) Shen-Yan-Yi-Hao Oral Solution Ameliorates Iga Nephropathy via Intestinal IL-17/NF-κB Pathway. Journal of Ethnopharmacology, 331, Article 118335.
https://doi.org/10.1016/j.jep.2024.118335

为你推荐